microRNAs in stroke pathogenesis

J. R. Tan, Yu X Koo, P. Kaur, F. Liu, Arunmozhiarasi Armugam, P. T H Wong, K. Jeyaseelan

Research output: Contribution to journalReview ArticleResearchpeer-review

75 Citations (Scopus)

Abstract

Stroke is one of the leading causes of death and disability worldwide. There are two major types of stroke: cerebral ischemia caused by obstruction of blood vessels in the brain and haemorrhagic stroke that is triggered by the disruption of blood vessels. Thrombolytic therapy involving recombinant tissue plasminogen activator (rtPA) has been shown to be beneficial only when used within 4.5 hours of onset of acute ischemic stroke. rtPA treatment beyond this time window has been found to be unsuitable and usually resulting in haemorrhagic transformation. Stroke is a multifactorial disease that forms a possible end state for majority of patients suffering from diabetes, atherosclerosis and hypertension which are known risk factors. Although the biochemistry of stroke and related diseases is quite well understood, the knowledge on the molecular mechanisms underlying these diseases is still at its infancy. microRNAs that form a unique class of endogenous riboregulators of gene function, offer tremendous potential in unraveling the mechanisms underlying stroke pathogenesis. microRNA expression also reflects the response of individuals to drugs and therapy. Several microRNAs and their target genes, known to be involved in endothelial dysfunction, dysregulation of neurovascular integrity, edema formation, pro-apoptosis, inflammation and extra-cellular matrix remodeling contribute to the critical processes in the pathogenesis of stroke. In this review, we will also be discussing the role of microRNAs as possible diagnostic and prognostic biomarkers as well as potential therapeutic targets in stroke pathogenesis.

Original languageEnglish
Pages (from-to)76-92
Number of pages17
JournalCurrent Molecular Medicine
Volume11
Issue number2
DOIs
Publication statusPublished - 2011
Externally publishedYes

Keywords

  • Cerebral ischemia
  • Hemorrhagic transformation
  • MiRNA
  • Neurogenesis
  • Pathogenesis
  • Risk factors

Cite this

Tan, J. R., Koo, Y. X., Kaur, P., Liu, F., Armugam, A., Wong, P. T. H., & Jeyaseelan, K. (2011). microRNAs in stroke pathogenesis. Current Molecular Medicine, 11(2), 76-92. https://doi.org/10.2174/156652411794859232
Tan, J. R. ; Koo, Yu X ; Kaur, P. ; Liu, F. ; Armugam, Arunmozhiarasi ; Wong, P. T H ; Jeyaseelan, K. / microRNAs in stroke pathogenesis. In: Current Molecular Medicine. 2011 ; Vol. 11, No. 2. pp. 76-92.
@article{47ab4de505c046689f5a5cabd9814409,
title = "microRNAs in stroke pathogenesis",
abstract = "Stroke is one of the leading causes of death and disability worldwide. There are two major types of stroke: cerebral ischemia caused by obstruction of blood vessels in the brain and haemorrhagic stroke that is triggered by the disruption of blood vessels. Thrombolytic therapy involving recombinant tissue plasminogen activator (rtPA) has been shown to be beneficial only when used within 4.5 hours of onset of acute ischemic stroke. rtPA treatment beyond this time window has been found to be unsuitable and usually resulting in haemorrhagic transformation. Stroke is a multifactorial disease that forms a possible end state for majority of patients suffering from diabetes, atherosclerosis and hypertension which are known risk factors. Although the biochemistry of stroke and related diseases is quite well understood, the knowledge on the molecular mechanisms underlying these diseases is still at its infancy. microRNAs that form a unique class of endogenous riboregulators of gene function, offer tremendous potential in unraveling the mechanisms underlying stroke pathogenesis. microRNA expression also reflects the response of individuals to drugs and therapy. Several microRNAs and their target genes, known to be involved in endothelial dysfunction, dysregulation of neurovascular integrity, edema formation, pro-apoptosis, inflammation and extra-cellular matrix remodeling contribute to the critical processes in the pathogenesis of stroke. In this review, we will also be discussing the role of microRNAs as possible diagnostic and prognostic biomarkers as well as potential therapeutic targets in stroke pathogenesis.",
keywords = "Cerebral ischemia, Hemorrhagic transformation, MiRNA, Neurogenesis, Pathogenesis, Risk factors",
author = "Tan, {J. R.} and Koo, {Yu X} and P. Kaur and F. Liu and Arunmozhiarasi Armugam and Wong, {P. T H} and K. Jeyaseelan",
year = "2011",
doi = "10.2174/156652411794859232",
language = "English",
volume = "11",
pages = "76--92",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers",
number = "2",

}

Tan, JR, Koo, YX, Kaur, P, Liu, F, Armugam, A, Wong, PTH & Jeyaseelan, K 2011, 'microRNAs in stroke pathogenesis', Current Molecular Medicine, vol. 11, no. 2, pp. 76-92. https://doi.org/10.2174/156652411794859232

microRNAs in stroke pathogenesis. / Tan, J. R.; Koo, Yu X; Kaur, P.; Liu, F.; Armugam, Arunmozhiarasi; Wong, P. T H; Jeyaseelan, K.

In: Current Molecular Medicine, Vol. 11, No. 2, 2011, p. 76-92.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - microRNAs in stroke pathogenesis

AU - Tan, J. R.

AU - Koo, Yu X

AU - Kaur, P.

AU - Liu, F.

AU - Armugam, Arunmozhiarasi

AU - Wong, P. T H

AU - Jeyaseelan, K.

PY - 2011

Y1 - 2011

N2 - Stroke is one of the leading causes of death and disability worldwide. There are two major types of stroke: cerebral ischemia caused by obstruction of blood vessels in the brain and haemorrhagic stroke that is triggered by the disruption of blood vessels. Thrombolytic therapy involving recombinant tissue plasminogen activator (rtPA) has been shown to be beneficial only when used within 4.5 hours of onset of acute ischemic stroke. rtPA treatment beyond this time window has been found to be unsuitable and usually resulting in haemorrhagic transformation. Stroke is a multifactorial disease that forms a possible end state for majority of patients suffering from diabetes, atherosclerosis and hypertension which are known risk factors. Although the biochemistry of stroke and related diseases is quite well understood, the knowledge on the molecular mechanisms underlying these diseases is still at its infancy. microRNAs that form a unique class of endogenous riboregulators of gene function, offer tremendous potential in unraveling the mechanisms underlying stroke pathogenesis. microRNA expression also reflects the response of individuals to drugs and therapy. Several microRNAs and their target genes, known to be involved in endothelial dysfunction, dysregulation of neurovascular integrity, edema formation, pro-apoptosis, inflammation and extra-cellular matrix remodeling contribute to the critical processes in the pathogenesis of stroke. In this review, we will also be discussing the role of microRNAs as possible diagnostic and prognostic biomarkers as well as potential therapeutic targets in stroke pathogenesis.

AB - Stroke is one of the leading causes of death and disability worldwide. There are two major types of stroke: cerebral ischemia caused by obstruction of blood vessels in the brain and haemorrhagic stroke that is triggered by the disruption of blood vessels. Thrombolytic therapy involving recombinant tissue plasminogen activator (rtPA) has been shown to be beneficial only when used within 4.5 hours of onset of acute ischemic stroke. rtPA treatment beyond this time window has been found to be unsuitable and usually resulting in haemorrhagic transformation. Stroke is a multifactorial disease that forms a possible end state for majority of patients suffering from diabetes, atherosclerosis and hypertension which are known risk factors. Although the biochemistry of stroke and related diseases is quite well understood, the knowledge on the molecular mechanisms underlying these diseases is still at its infancy. microRNAs that form a unique class of endogenous riboregulators of gene function, offer tremendous potential in unraveling the mechanisms underlying stroke pathogenesis. microRNA expression also reflects the response of individuals to drugs and therapy. Several microRNAs and their target genes, known to be involved in endothelial dysfunction, dysregulation of neurovascular integrity, edema formation, pro-apoptosis, inflammation and extra-cellular matrix remodeling contribute to the critical processes in the pathogenesis of stroke. In this review, we will also be discussing the role of microRNAs as possible diagnostic and prognostic biomarkers as well as potential therapeutic targets in stroke pathogenesis.

KW - Cerebral ischemia

KW - Hemorrhagic transformation

KW - MiRNA

KW - Neurogenesis

KW - Pathogenesis

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=79952807964&partnerID=8YFLogxK

U2 - 10.2174/156652411794859232

DO - 10.2174/156652411794859232

M3 - Review Article

VL - 11

SP - 76

EP - 92

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 2

ER -

Tan JR, Koo YX, Kaur P, Liu F, Armugam A, Wong PTH et al. microRNAs in stroke pathogenesis. Current Molecular Medicine. 2011;11(2):76-92. https://doi.org/10.2174/156652411794859232